Anaplastic thyroid carcinoma, version 2.2015

Robert I. Haddad, William M. Lydiatt, Douglas W. Ball, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, Quan Yang Duh, Hormoz Ehya, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, Judith C. McCaffrey, Jeffrey F. Moley, Lee Parks, Christopher D. RaeburnJohn A. Ridge, Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Robert C. Smallridge, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Karin G. Hoffmann, Miranda Hughes

Research output: Contribution to journalReview article

42 Scopus citations

Abstract

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosages and frequency of administration are now provided, docetaxel/doxorubicin regimens were added, and single-agent cisplatin was deleted because it is not recommended for patients with advanced or metastatic anaplastic thyroid cancer.

Original languageEnglish (US)
Pages (from-to)1140-1150
Number of pages11
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume13
Issue number9
DOIs
StatePublished - Sep 1 2015

    Fingerprint

ASJC Scopus subject areas

  • Oncology

Cite this

Haddad, R. I., Lydiatt, W. M., Ball, D. W., Busaidy, N. L., Byrd, D., Callender, G., Dickson, P., Duh, Q. Y., Ehya, H., Haymart, M., Hoh, C., Hunt, J. P., Iagaru, A., Kandeel, F., Kopp, P., Lamonica, D. M., McCaffrey, J. C., Moley, J. F., Parks, L., ... Hughes, M. (2015). Anaplastic thyroid carcinoma, version 2.2015. JNCCN Journal of the National Comprehensive Cancer Network, 13(9), 1140-1150. https://doi.org/10.6004/jnccn.2015.0139